Ensemble is developing a novel class of therapeutics, called Ensemblins™, which open up new ways to treat diseases by addressing drug targets that are currently inaccessible with conventional small molecule drugs. Ensemblins are synthetic macrocycles that have a distinct ring structure, which confers an unprecedented combination of chemical and biologic properties that stretch the therapeutic potential of small molecule drugs.

With their unique macrocyclic structure, Ensemblins are a new class of drugs in the emerging therapeutic space between small molecules and biologics. Ensemblins are orally-active therapeutics with unique properties for binding to human disease targets, including targets that are currently only accessible with costly, injectable biologic drugs or currently undruggable intra-cellular targets.

With its proprietary DNA-programmed drug discovery platform, Ensemble is the first company to successfully and reliably engineer synthetic macrocycle drugs, a class of compounds that have traditionally existed principally as natural products but have resulted in over 100 marketed products.

Ensemble has made strong progress in developing a pipeline of macrocycle product candidates, and is pursuing a business strategy to develop Ensemblins through its own internal product development programs and through partnerships with pharmaceutical companies. The company is leveraging the potential of its powerful product engine by developing Ensemblins to treat a broad range of diseases, including inflammation, oncology and diabetes.

Ensemble has a strong core foundation, including an experienced management team and solid financial resources. To date, the company has raised $38.5 million in equity financing, attracted leading venture capitalists, and established valuable alliances with blue-chip pharmaceutical companies.

[ back to top ]